Dr Reddy S Labs Profit
- All
- News
- Videos
-
Dr Reddy's Laboratories Net Profit Rises 30% To Rs 992 Crore In September Quarter
Dr Reddy's Q2 Results: The pharma major's revenue from operations in the second quarter of the current fiscal stood at Rs 5,763 crore, compared to Rs 4,896 crore in the same quarter last year
-
Dr Reddy's Labs Sheds 11% After Profit Falls 1.5% To Rs 570 Crore In June Quarter
Dr Reddy's Share Price Today: On Tuesday, Dr Reddy's Labs opened on the BSE at Rs 5,421, inching to an intra day high of Rs 5,445, and an intra day low of Rs 4,786.26, so far
-
Dr Reddy's Lab Net Profit Declines 28% To Rs 553.5 Crore In March Quarter
Dr Reddy's Lab Q4 FY21 Results: Dr Reddy's Laboratories announced its January-March quarter results, reporting a 27.5 per cent decline in net profit year-on-year at Rs 553.5 crore.
-
Stocks To Watch In Trade: HDFC Bank, Dr Reddy's Lab, Wipro
HDFC Bank, on Saturday, reported a 18.1 rise in net profit to Rs 8,758.3 crore in the October-December quarter; total income increased to Rs 37,522 crore compared to Rs 36,039 crore in the year-ago period
-
Dr Reddy's Laboratories June Quarter Profit Declines 13% To Rs 579 Crore
Dr Reddy's Laboratories said its revenue from North America rose 6 per cent to Rs 1,730 crore, driven by contribution from new product launches.
-
Dr Reddy's Labs Reports Profit Of Rs 663 Crore In June Quarter
The company said its research and development (R&D) expenses stood at Rs 361 crore in the quarter ended June 30.
-
Sensex Closes Lower For Seventh Day, Its Longest Losing Streak In A Year
JSW Steel, Dr Reddy's Labs, Sun Pharma, Hero MotoCorp and Tata Steel were among the top Nifty losers.
-
Sensex Falls For Third Straight Day On Global Growth Concerns
Seventeen of 19 sector gauges compiled by BSE ended lower led by the S&P BSE Healthcare Index's nearly 2 per cent decline.
-
Dr Reddy's Second-Quarter Profit Jumps Nearly 70% To 518 Crore Rupees
Dr Reddy's Laboratories revenue in the global generics segment from emerging markets surged 36 per cent to Rs 749 crore.
-
Sensex Falls 215 Points, Nifty Settles At 10,628; Banks Lead Declines
The S&P BSE Sensex on Monday slipped 215 points to close at 35,011.89 while the National Stock Exchange (NSE) benchmark index Nifty50 settled at 10,628. The stock market ended lower for the second consecutive session on Monday, dragged by financials amid caution during the RBI's three-day interest rate-setting meeting. Dr Reddys Labs, Infosys, Mahi...
-
Sensex, Nifty Edge Lower; Aurobindo Pharma, Dr Reddy's Lab, Cipla Among Top Losers
The broader markets were weak today with BSE midcap and smallcap indices falling nearly 1.5 per cent. Healthcare, metal and capital goods led the losers.
-
Dr Reddy's Labs Q2 Profit Falls 1% to Rs 305 Crore
Dr Reddy's Labs total revenue from operations in Q2 stood at Rs 3,559.8 crore, down 1.56 per cent
-
Sensex Ends 28 Points Higher, Aurobindo Pharma Jumps 5%
The pharma sub-index of NSE, Nifty Pharma, rose 3.32 per cent lead by gains in Aurobindo Pharma, Lupin, Sun pharma, Dr Reddy's Lab and Cipla,
-
Dr Reddy's Lab's Stock Down 6%, Losses Extend To Second Day
Due to falling US sales and GST, Dr Reddy's Laboratories net profit fell more than 56 per cent for the June quarter.
-
Dr.Reddy's First-Quarter Profit Slumps 57%
The company, among India's top 5 drugmakers, reported a net profit after tax and share of profit of associates of Rs 66.6 crore, versus Rs 154 crore a year ago, the company said on Thursday.
-
Dr Reddy's Laboratories Net Profit Rises 30% To Rs 992 Crore In September Quarter
Dr Reddy's Q2 Results: The pharma major's revenue from operations in the second quarter of the current fiscal stood at Rs 5,763 crore, compared to Rs 4,896 crore in the same quarter last year
-
Dr Reddy's Labs Sheds 11% After Profit Falls 1.5% To Rs 570 Crore In June Quarter
Dr Reddy's Share Price Today: On Tuesday, Dr Reddy's Labs opened on the BSE at Rs 5,421, inching to an intra day high of Rs 5,445, and an intra day low of Rs 4,786.26, so far
-
Dr Reddy's Lab Net Profit Declines 28% To Rs 553.5 Crore In March Quarter
Dr Reddy's Lab Q4 FY21 Results: Dr Reddy's Laboratories announced its January-March quarter results, reporting a 27.5 per cent decline in net profit year-on-year at Rs 553.5 crore.
-
Stocks To Watch In Trade: HDFC Bank, Dr Reddy's Lab, Wipro
HDFC Bank, on Saturday, reported a 18.1 rise in net profit to Rs 8,758.3 crore in the October-December quarter; total income increased to Rs 37,522 crore compared to Rs 36,039 crore in the year-ago period
-
Dr Reddy's Laboratories June Quarter Profit Declines 13% To Rs 579 Crore
Dr Reddy's Laboratories said its revenue from North America rose 6 per cent to Rs 1,730 crore, driven by contribution from new product launches.
-
Dr Reddy's Labs Reports Profit Of Rs 663 Crore In June Quarter
The company said its research and development (R&D) expenses stood at Rs 361 crore in the quarter ended June 30.
-
Sensex Closes Lower For Seventh Day, Its Longest Losing Streak In A Year
JSW Steel, Dr Reddy's Labs, Sun Pharma, Hero MotoCorp and Tata Steel were among the top Nifty losers.
-
Sensex Falls For Third Straight Day On Global Growth Concerns
Seventeen of 19 sector gauges compiled by BSE ended lower led by the S&P BSE Healthcare Index's nearly 2 per cent decline.
-
Dr Reddy's Second-Quarter Profit Jumps Nearly 70% To 518 Crore Rupees
Dr Reddy's Laboratories revenue in the global generics segment from emerging markets surged 36 per cent to Rs 749 crore.
-
Sensex Falls 215 Points, Nifty Settles At 10,628; Banks Lead Declines
The S&P BSE Sensex on Monday slipped 215 points to close at 35,011.89 while the National Stock Exchange (NSE) benchmark index Nifty50 settled at 10,628. The stock market ended lower for the second consecutive session on Monday, dragged by financials amid caution during the RBI's three-day interest rate-setting meeting. Dr Reddys Labs, Infosys, Mahi...
-
Sensex, Nifty Edge Lower; Aurobindo Pharma, Dr Reddy's Lab, Cipla Among Top Losers
The broader markets were weak today with BSE midcap and smallcap indices falling nearly 1.5 per cent. Healthcare, metal and capital goods led the losers.
-
Dr Reddy's Labs Q2 Profit Falls 1% to Rs 305 Crore
Dr Reddy's Labs total revenue from operations in Q2 stood at Rs 3,559.8 crore, down 1.56 per cent
-
Sensex Ends 28 Points Higher, Aurobindo Pharma Jumps 5%
The pharma sub-index of NSE, Nifty Pharma, rose 3.32 per cent lead by gains in Aurobindo Pharma, Lupin, Sun pharma, Dr Reddy's Lab and Cipla,
-
Dr Reddy's Lab's Stock Down 6%, Losses Extend To Second Day
Due to falling US sales and GST, Dr Reddy's Laboratories net profit fell more than 56 per cent for the June quarter.
-
Dr.Reddy's First-Quarter Profit Slumps 57%
The company, among India's top 5 drugmakers, reported a net profit after tax and share of profit of associates of Rs 66.6 crore, versus Rs 154 crore a year ago, the company said on Thursday.
